4.8 Article

EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis

Journal

CANCER CELL
Volume 30, Issue 2, Pages 197-213

Publisher

CELL PRESS
DOI: 10.1016/j.ccell.2016.07.006

Keywords

-

Funding

  1. Charles Revson Senior Fellowship in Biomedical Science
  2. American Society of Hematology Scholar Award
  3. NIH [5F30HL093996, 5T32GM008244]
  4. AHA [0810194Z]
  5. University of Minnesota Wetzel Fund
  6. NCI [R01 CA071540, R01 CA187109]
  7. Minnesota Masonic Charities
  8. University of Minnesota Medical School and Office of the Vice President for Research
  9. LLS TRP [6141-14]
  10. Janssen
  11. Eli Lilly
  12. GSK
  13. Roche

Ask authors/readers for more resources

The EZH2 histone methyltransferase mediates the humoral immune response and drives lymphomagenesis through formation of bivalent chromatin domains at critical germinal center (GC) B cell promoters. Herein we show that the actions of EZH2 in driving GC formation and lymphoma precursor lesions require site-specific binding by the BCL6 transcriptional repressor and the presence of a non-canonical PRC1-BCOR-CBX8 complex. The chromodomain protein CBX8 is induced in GC B cells, binds to H3K27me3 at bivalent promoters, and is required for stable association of the complex and the resulting histone modifications. Moreover, oncogenic BCL6 and EZH2 cooperate to accelerate diffuse large B cell lymphoma (DLBCL) development and combinatorial targeting of these repressors results in enhanced anti-lymphoma activity in DLBCLs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available